Skip to Content

Adicet Bio Inc Ordinary Shares ACET

Morningstar Rating
$2.35 +0.02 (0.86%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ACET is trading at a 67% discount.
Price
$2.23
Fair Value
$7.19
Uncertainty
Extreme
1-Star Price
$29.46
5-Star Price
$3.65
Economic Moat
Yycbt
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACET is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.33
Day Range
$2.312.40
52-Week Range
$1.107.50
Bid/Ask
$2.32 / $2.35
Market Cap
$193.06 Mil
Volume/Avg
534,078 / 1.6 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
143

Comparables

Valuation

Metric
ACET
ANAB
RCUS
Price/Earnings (Normalized)
Price/Book Value
0.606.452.98
Price/Sales
33.5511.52
Price/Cash Flow
Price/Earnings
ACET
ANAB
RCUS

Financial Strength

Metric
ACET
ANAB
RCUS
Quick Ratio
8.2810.624.35
Current Ratio
8.4110.874.52
Interest Coverage
−6,104.44−9.09−170.00
Quick Ratio
ACET
ANAB
RCUS

Profitability

Metric
ACET
ANAB
RCUS
Return on Assets (Normalized)
−38.02%−23.50%−20.42%
Return on Equity (Normalized)
−44.28%−75.96%−44.44%
Return on Invested Capital (Normalized)
−44.36%−68.56%−49.53%
Return on Assets
ACET
ANAB
RCUS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRZskmxrqbgYfgqc$570.1 Bil
VRTX
Vertex Pharmaceuticals IncFtylwrxtYzgjkk$107.8 Bil
REGN
Regeneron Pharmaceuticals IncDdmlndzbSvbbkp$105.6 Bil
MRNA
Moderna IncYyfpwxtxNpgy$40.8 Bil
ARGX
argenx SE ADRXqysbvmQvykf$23.7 Bil
BNTX
BioNTech SE ADRWgrzsppsSrm$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncQstqqhjmTybgw$19.4 Bil
BMRN
Biomarin Pharmaceutical IncJsxlxknhCmrdgs$16.7 Bil
RPRX
Royalty Pharma PLC Class ASsbzjjxrhYwkpxbc$13.6 Bil
INCY
Incyte CorpTqlzlhbfLnfdm$12.8 Bil

Sponsor Center